Peptides DB
Research-centric peptide and protocol reference hub
Study 46 of 46NAD+ (Nicotinamide Adenine Dinucleotide) literaturebiorxiv-preprint · Observational2026

NAD metabolism mediates a sex-specific protection against early life infections

NAD metabolism may play a role in sex-specific immune responses in early life, with higher levels in females linked to better infection outcomes.

Read at biorxiv-preprintAdd to compare

Where it sits

this study against the rest of the nad+ (nicotinamide adenine dinucleotide) corpus
17
Preclinical
22
Observational · this one
1
Open-label
1
Randomised
5
Reviews

Summary and findings

This study investigated the role of NAD metabolism in sex-specific immunity and infection outcomes in early life. It involved two cohorts of children and a piglet model, examining NAD levels and the effects of nicotinamide riboside supplementation. Results indicated higher NAD levels in females at birth correlated with reduced infection burdens, while males showed increased burdens.

How much of this paper we could read: full text read (0.70). We had a clear abstract, so the summary below closely tracks the paper. What this means →
Higher birth NAD levels in females were associated with reduced infection burdens during the first 3 years of life.2026

Abstract

The authors’ words, as biorxiv-preprint supplied them

Sex influences early-life immunity and infection outcomes, yet how metabolic mechanisms regulate these effects remain unclear. As nicotinamide adenine dinucleotide (NAD) can support mitochondrial metabolism and immune function, here we explore how NAD metabolism contributes to sex-specific protection against infections in early life. First, in two independent cohorts of 700 and 386 children, we found that females at birth had higher blood NAD levels than males, and strikingly higher birth NAD levels were associated with reduced infection burdens during the first 3 years of life in females, but with tendency of increased burdens in males. At 18 months, plasma nicotinamide associated with sex-specific cytokine responses to antigen challenges and showed a stronger positive association with tricarboxylic acid cycle (TCA) activity in females. Next, we verified the causal effects of NAD metabolism on infection protection by testing the supplementation of NAD precursor nicotinamide riboside (NR) in infected newborn piglets, used as a translational model of infection-sensitive infants. NR treatment improved survival, bacterial clearance, and disease tolerance only in females, but not in males. Mechanistically, NR increased levels of hepatic TCA cycle metabolites fumarate and malate, and enhanced hepatic inflammatory, hormonal, and mitochondrial-associated transcriptional programs, again only in females. Finally, the sex-specific immune functions mediated by NR were also validated in blood and immune cells in vitro. Collectively, we identified NAD metabolism as a sex-dependent immunometabolic mediator in early-life infection. Our findings suggest the potential of sex-stratified nutritional interventions in infection-sensitive infants.

Background

Not reported in abstract.

Methods

Not reported in abstract.

Results

Not reported in abstract.

Interpretation

Not reported in abstract.

Limitations

Not reported in abstract.

Elsewhere in the NAD+ (Nicotinamide Adenine Dinucleotide) corpus

BControl-referenced bacterial bioluminescence reveals a two-axis salivary response phenotype in benign and malignant breast disease.Talanta · 2026 · n=200 · Not reported in abstract.HumanBGenetic modulation of NAD(P)H homeostasis reveals distinct redox-coupled metabolic vulnerabilities.Nature metabolism · 2026 · Not reported in abstract.HumanDA context-dependent framework for targeting NAD metabolism in cancer.Cell metabolism · 2026reviewBPart 1 of a 2-part, open-label clinical trial evaluating repeated nicotinamide riboside parenteral administration: 3 consecutive days of intramuscular and subcutaneous injectionsbiorxiv-preprint · 2026 · 9.97% average daily increase in NAD+ for 100 mg IM.HumanBPart 2 of a 2-part open-label clinical trial evaluating repeated nicotinamide riboside parenteral administration: 90 days of at-home subcutaneous injectionsbiorxiv-preprint · 2026 · GlycoATP decreased at Day 30, p<0.05.HumanDAn NAD(+)-responsive adipose signal coordinates inter-organ defense against muscle atrophy.Cell metabolism · 2026—